Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet …
Insiders
Transactions
| Reported Owner(s) | Position Now | Transaction Date | Type | Position Change | Extra | ||
|---|---|---|---|---|---|---|---|
|
$233,669
d
cs
10% Holder
|
12/15/24 |
F
|
6,132 x $0.59 = $3,617.88 |
Footnotes
#1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of December 15, 2024.
|
|||
|
$78,125
d
cs
10% Holder
|
06/18/24 |
P
|
20,000 x $0.68 = $13,600.00 |
Footnotes
|
|||
|
$239,801
d
cs
10% Holder
|
06/12/24 |
F
|
2,007 x $0.76 = $1,525.32 |
Footnotes
#1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of June 12, 2024.
|
|||
|
$40,566
d
cs
10% Holder
|
06/11/24 |
A
|
16,000 x $0 = $0 |
Footnotes
#1 Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025, the first anniversary date of the grant.
|
|||
|
$686,840
d
cs
10% Holder
|
06/11/24 |
A
|
16,000 x $0 = $0 |
Footnotes
#1 Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025, the first anniversary date of the grant.
|
|||
Get PRO Today
With PRO you will unlock 60 more insider transactions for Vaxart, Inc.
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Ahmad Fuad Interim CFO
- Berg Edward B SVP, General Counsel
- Cherrington Julie M Director
- Cummings James F. Chief Medical Officer
- Davis Todd C Director
- Finney Michael J. Director
- Floroiu Cezar Andrei President, Chief Exec Officer
- Heron Elaine J Director
- Lee Phillip E Chief Financial Officer
- Lo Steven President, Chief Exec Officer
- Tucker Sean SVP, Chief Scientific Officer
- Watson W. Mark Director
- Wheadon David E. Director
- Yedid Robert A. Director
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Ahmad Fuad Interim CFO
- Berg Edward B SVP, General Counsel
- Cherrington Julie M Director
- Cummings James F. Chief Medical Officer
- Davis Todd C Director
- Finney Michael J. Director
- Floroiu Cezar Andrei President, Chief Exec Officer
- Heron Elaine J Director
- Lee Phillip E Chief Financial Officer
- Lo Steven President, Chief Exec Officer
- Tucker Sean SVP, Chief Scientific Officer
- Watson W. Mark Director
- Wheadon David E. Director
- Yedid Robert A. Director